^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    nafamostat

    i
    Other names: FUT-175, CKD-314
    Company:
    Generic mfg.
    Drug class:
    TMPRSS2 inhibitor, Serine protease inhibitor
    Related drugs:
    3d
    Comparison of Anticoagulant Effects Between Nafamostat Mesylate and Sodium Citrate in Double Filtration Plasmapheresis (ChiCTR2600117445)
    P=N/A, N=140, Not yet recruiting, The First Affiliated Hospital of Army Medical University PLA; The First Affiliated Hospital of Army Medical University PLA
    New trial
    |
    nafamostat
    3d
    A Randomized, Active-Controlled, Open-Label Clinical Study of Nafamostat Mesylate for Reducing Bleeding Risk in Maintenance Hemodialysis Patients at High Risk of Bleeding (ChiCTR2600116304)
    P=N/A, N=338, Not yet recruiting, The Seventh Affiliated Hospital Sun Yat-sen University; The Seventh Affiliated Hospital of Sun Yat-sen University
    New trial
    |
    nafamostat • enoxaparin sodium
    2ms
    Effect of extracorporeal anticoagulation with nafamostat mesilate and continuous renal replacement therapy on sepsis complicated with acute kidney injury. (PubMed, Int J Clin Pharmacol Ther)
    NM outperforms RCA in prolonging the hemofilter lifespan, reducing hemofilter replacement frequency, improving renal perfusion and renal function, and eliminating inflammatory mediators.
    Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha)
    |
    nafamostat
    3ms
    Multifaceted anticancer activity of nafamostat mesylate in human fibrosarcoma: first evidence of mitochondrial apoptosis and suppressed MMP-2/-9 mRNA expression. (PubMed, BMC Pharmacol Toxicol)
    This study provides the first evidence that nafamostat mesylate exerts multifaceted anticancer effects in HT1080 fibrosarcoma cells, targeting proliferation, migration, apoptosis, and invasion. These findings support the potential repurposing of nafamostat mesylate as a therapeutic agent for fibrosarcoma and warrant further preclinical investigations to evaluate its translational applicability.
    Journal
    |
    MMP2 (Matrix metallopeptidase 2) • MMP9 (Matrix metallopeptidase 9) • ANXA5 (Annexin A5)
    |
    nafamostat
    3ms
    Comparison of the efficacy and safety of nafamostat mesylate and heparin in blood purification therapy for patients with severe acute pancreatitis: A randomized controlled trial (ChiCTR2500111161)
    P4, N=140, Not yet recruiting, Weifang People's Hospital; Weifang People's Hospital
    New P4 trial
    |
    nafamostat
    3ms
    The Safety and Efficacy of Different Anticoagulation Strategies in Double Filtration Plasmapheresis Therapy (ChiCTR2500109547)
    P=N/A, N=300, Not yet recruiting, West China Hospital of Sichuan University; West China Hospital of Sichuan University
    New trial
    |
    nafamostat
    3ms
    Clinical research on nafamostat mesylate for injection (ChiCTR2500107352)
    P3, N=220, Not yet recruiting, The Second Affiliated Hospital of Nanjing Medical University; The Second Affiliated Hospital of Nanjing Medical University
    New P3 trial
    |
    nafamostat
    4ms
    NEPHRO: Nafamostat Efficacy in Phase 3 Registrational CRRT Study (clinicaltrials.gov)
    P=N/A, N=70, Recruiting, Talphera, Inc | N=166 --> 70
    Enrollment change
    |
    nafamostat
    4ms
    NEPHRO: Nafamostat Efficacy in Phase 3 Registrational CRRT Study (clinicaltrials.gov)
    P=N/A, N=166, Recruiting, Talphera, Inc | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    nafamostat
    6ms
    Feasibility study of blood sample collection from hemodialysis extracorporeal circulation circuit instead of blood vessel for monitoring the anticoagulant effect of nafamostat mesylate in continuous blood purification therapy (ChiCTR2500107232)
    P=N/A, N=0, Not yet recruiting, Aerospace Center Hospital; Aerospace Center Hospital
    New trial
    |
    nafamostat
    6ms
    DEFINE - Evaluating Therapies for COVID-19 (clinicaltrials.gov)
    P1/2, N=71, Completed, University of Edinburgh | Recruiting --> Completed | N=200 --> 71
    Trial completion • Enrollment change
    |
    nafamostat
    6ms
    Comparative Study of Citrate versus Nafamostat for CRRT in Patients with Sepsis-Associated Acute Kidney Injury (ChiCTR2500106976)
    P=N/A, N=112, Not yet recruiting, Zhongnan Hospital of Wuhan University; Zhongnan Hospital of Wuhan University
    New trial
    |
    nafamostat